INVO Fertility, Inc. IVF
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-19.01
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $6.8M | -$23.3M | — | -$7.1M | $7.2M |
| 2024 | $6.5M | -$9.3M | — | -$3.2M | $12.6M |
| 2023 | $3.0M | -$8.0M | — | -$5.2M | $892,825 |
| 2022 | $822,196 | -$10.9M | $490,673 | -$6.6M | -$977,612 |
| 2021 | $4.2M | -$6.7M | $4.0M | -$6.4M | $7.3M |
| 2020 | $1.0M | -$8.3M | $948,526 | -$4.8M | $5.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.01 (distress)
- Working capital / assets -0.374
- Retained earnings / assets -4.519
- EBIT / assets -0.358
- Equity / liabilities 0.556
Source: SEC EDGAR filings · CIK 0001417926 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.